Image enhancement endoscopy

Stephan M. Wildi, Michael B. Wallace

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Endoscopy altered the practice of gastroenterology by providing nonoperative access to the gastrointestinal (GI) tract and the pancreaticobiliary system. The detection of microscopic and biochemical changes within the mucosa and submucosa, however, has remained beyond the realm of routine endoscopy. Distinguishing hyperplastic from neoplastic polyps, differentiating malignant from benign ulcers, and detecting mucosal dysplasia in patients with inflammatory bowel disease or Barrett's esophagus (BE) remains within the purview of the GI pathologist. In particular, endoscopic detection of dysplasia relies on the recognition of visible lesions (e.g., adenomatous polyps, dysplasia-associated lesion, or mass), or random sampling of tissue (biopsy). Endoscopy alone can neither reliably detect regions of invisible or flat dysplasia nor distinguish dysplasia from nondysplastic changes within visible lesions. Histological examination of the excised material is required to diagnose and locate dysplasia. Random biopsy techniques are subject to sampling errors and increased risk because of long procedure time and multiple biopsy sites. In patients with inflammatory bowel disease, it has been estimated that a total of 33 and 56 biopsy specimens are required for a 90 and 95% confidence to detect dysplasia or carcinoma (1).

Original languageEnglish (US)
Title of host publicationEndoscopic Oncology: Gastrointestinal Endoscopy and Cancer Management
PublisherHumana Press
Pages17-30
Number of pages14
ISBN (Print)158829532X, 9781588295323
DOIs
StatePublished - 2006

Fingerprint

Image Enhancement
Endoscopy
Biopsy
Inflammatory Bowel Diseases
Adenomatous Polyps
Barrett Esophagus
Selection Bias
Gastroenterology
Polyps
Ulcer
Gastrointestinal Tract
Mucous Membrane
Carcinoma

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Wildi, S. M., & Wallace, M. B. (2006). Image enhancement endoscopy. In Endoscopic Oncology: Gastrointestinal Endoscopy and Cancer Management (pp. 17-30). Humana Press. https://doi.org/10.1007/978-1-59745-172-7_3

Image enhancement endoscopy. / Wildi, Stephan M.; Wallace, Michael B.

Endoscopic Oncology: Gastrointestinal Endoscopy and Cancer Management. Humana Press, 2006. p. 17-30.

Research output: Chapter in Book/Report/Conference proceedingChapter

Wildi, SM & Wallace, MB 2006, Image enhancement endoscopy. in Endoscopic Oncology: Gastrointestinal Endoscopy and Cancer Management. Humana Press, pp. 17-30. https://doi.org/10.1007/978-1-59745-172-7_3
Wildi SM, Wallace MB. Image enhancement endoscopy. In Endoscopic Oncology: Gastrointestinal Endoscopy and Cancer Management. Humana Press. 2006. p. 17-30 https://doi.org/10.1007/978-1-59745-172-7_3
Wildi, Stephan M. ; Wallace, Michael B. / Image enhancement endoscopy. Endoscopic Oncology: Gastrointestinal Endoscopy and Cancer Management. Humana Press, 2006. pp. 17-30
@inbook{2de7fd8f0b6b4946af849dfe0e29f546,
title = "Image enhancement endoscopy",
abstract = "Endoscopy altered the practice of gastroenterology by providing nonoperative access to the gastrointestinal (GI) tract and the pancreaticobiliary system. The detection of microscopic and biochemical changes within the mucosa and submucosa, however, has remained beyond the realm of routine endoscopy. Distinguishing hyperplastic from neoplastic polyps, differentiating malignant from benign ulcers, and detecting mucosal dysplasia in patients with inflammatory bowel disease or Barrett's esophagus (BE) remains within the purview of the GI pathologist. In particular, endoscopic detection of dysplasia relies on the recognition of visible lesions (e.g., adenomatous polyps, dysplasia-associated lesion, or mass), or random sampling of tissue (biopsy). Endoscopy alone can neither reliably detect regions of invisible or flat dysplasia nor distinguish dysplasia from nondysplastic changes within visible lesions. Histological examination of the excised material is required to diagnose and locate dysplasia. Random biopsy techniques are subject to sampling errors and increased risk because of long procedure time and multiple biopsy sites. In patients with inflammatory bowel disease, it has been estimated that a total of 33 and 56 biopsy specimens are required for a 90 and 95{\%} confidence to detect dysplasia or carcinoma (1).",
author = "Wildi, {Stephan M.} and Wallace, {Michael B.}",
year = "2006",
doi = "10.1007/978-1-59745-172-7_3",
language = "English (US)",
isbn = "158829532X",
pages = "17--30",
booktitle = "Endoscopic Oncology: Gastrointestinal Endoscopy and Cancer Management",
publisher = "Humana Press",

}

TY - CHAP

T1 - Image enhancement endoscopy

AU - Wildi, Stephan M.

AU - Wallace, Michael B.

PY - 2006

Y1 - 2006

N2 - Endoscopy altered the practice of gastroenterology by providing nonoperative access to the gastrointestinal (GI) tract and the pancreaticobiliary system. The detection of microscopic and biochemical changes within the mucosa and submucosa, however, has remained beyond the realm of routine endoscopy. Distinguishing hyperplastic from neoplastic polyps, differentiating malignant from benign ulcers, and detecting mucosal dysplasia in patients with inflammatory bowel disease or Barrett's esophagus (BE) remains within the purview of the GI pathologist. In particular, endoscopic detection of dysplasia relies on the recognition of visible lesions (e.g., adenomatous polyps, dysplasia-associated lesion, or mass), or random sampling of tissue (biopsy). Endoscopy alone can neither reliably detect regions of invisible or flat dysplasia nor distinguish dysplasia from nondysplastic changes within visible lesions. Histological examination of the excised material is required to diagnose and locate dysplasia. Random biopsy techniques are subject to sampling errors and increased risk because of long procedure time and multiple biopsy sites. In patients with inflammatory bowel disease, it has been estimated that a total of 33 and 56 biopsy specimens are required for a 90 and 95% confidence to detect dysplasia or carcinoma (1).

AB - Endoscopy altered the practice of gastroenterology by providing nonoperative access to the gastrointestinal (GI) tract and the pancreaticobiliary system. The detection of microscopic and biochemical changes within the mucosa and submucosa, however, has remained beyond the realm of routine endoscopy. Distinguishing hyperplastic from neoplastic polyps, differentiating malignant from benign ulcers, and detecting mucosal dysplasia in patients with inflammatory bowel disease or Barrett's esophagus (BE) remains within the purview of the GI pathologist. In particular, endoscopic detection of dysplasia relies on the recognition of visible lesions (e.g., adenomatous polyps, dysplasia-associated lesion, or mass), or random sampling of tissue (biopsy). Endoscopy alone can neither reliably detect regions of invisible or flat dysplasia nor distinguish dysplasia from nondysplastic changes within visible lesions. Histological examination of the excised material is required to diagnose and locate dysplasia. Random biopsy techniques are subject to sampling errors and increased risk because of long procedure time and multiple biopsy sites. In patients with inflammatory bowel disease, it has been estimated that a total of 33 and 56 biopsy specimens are required for a 90 and 95% confidence to detect dysplasia or carcinoma (1).

UR - http://www.scopus.com/inward/record.url?scp=84891427670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891427670&partnerID=8YFLogxK

U2 - 10.1007/978-1-59745-172-7_3

DO - 10.1007/978-1-59745-172-7_3

M3 - Chapter

AN - SCOPUS:84891427670

SN - 158829532X

SN - 9781588295323

SP - 17

EP - 30

BT - Endoscopic Oncology: Gastrointestinal Endoscopy and Cancer Management

PB - Humana Press

ER -